
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is positioned for growth in the biopharmaceutical market with a strong product portfolio and promising developments in their pipeline, particularly in the pediatric and orphan lung disease markets. Their strategic partnerships and focus on innovation and convenience give them a competitive edge, but delays and potential competition are potential risks to consider. Effective execution in clinical trials and regulatory processes will be crucial for the company's success in commercializing their products.
Bears say
MannKind is facing multiple risks such as commercial execution, clinical trials, and regulatory hurdles, which may hinder its ability to achieve its 12-month price target of $11. Additionally, the company's diverse pipeline may bring long-term growth opportunities, but carries risk as well. Competition from well-capitalized companies and potential challenges in the supply chain may also pose risks to MannKind's future market share and pricing power. Overall, the company's innovative dry powder drug delivery approach is a strong advantage, but it remains to be seen whether it will be enough to overcome the numerous risks that the company faces.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares